Cipla Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Keep track of all breaking news and updates on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

11 Apr 2025

1489.80

1.22%

Cipla gets USFDA nod to market generic version of cancer drug Abraxane

Business Standard

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.

Number of FII/FPI investors increased from 1077 to 1114 in Mar 2025 qtr.

Cipla gets USFDA nod for generic cancer drug

Business Line | 11 Apr 2025 1 more

Cipla Ltd.

11 Apr 2025

1489.80

1.22%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure …

BSE India

Company has received final approval from USFDA for ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (''Protein-bound Paclitaxel'') on 10th April, 2025

pdf

Cipla Ltd.

11 Apr 2025

1489.80

1.22%

Cipla (CIPLA IN) Event Update Gets approval for...

Buy: Cipla Ltd.

Prabhudas Lilladhar

Cipla has secured its much awaited USFDA approval of gAbraxane following Change in Estimates | Target | Reco the Goa facility clearance in November 2024, milestone that reinforces our positive stance on the company. Our FY26E and FY27E EPS factors in...

Cipla Ltd. is trading above its 150 day SMA of 1482.1

Cipla Ltd.

07 Apr 2025

1489.80

1.22%

Board Meeting

Cipla Ltd - 500087 - Board Meeting Intimation for Quarter And Year Ended 31St March 2025 …

BSE India

Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2025 ,inter alia, to consider and approve 1. the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March 2025. 2. Recommend final dividend for the year ended 31st March 2025, if any. In terms of the Company's Code of Conduct for Prevention of Insider Trading, the 'Trading Window' for dealing in the securities of the Company is closed from Tuesday, 1st April, 2025 till Thursday, 15th May, 2025 (both days inclusive) for the purpose of financial results.

pdf

Cipla Ltd.

22 Mar 2025

1489.80

1.22%

Cipla: Better positioned to grow and deal with tariff uncertainties

Business Line

All segments on strong footing to deliver long-term growth

Number of FII/FPI investors increased from 1077 to 1114 in Mar 2025 qtr.

Cipla Ltd.

19 Mar 2025

1489.80

1.22%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 19th March, 2025 has allotted 2,179 fully paid up equity shares of INR 2 each pursuant to exercise of employee stock options/stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.

pdf